Common Bone Drug Zoledronate Shows Powerful Anti-Aging Effects Beyond the Skeleton

Bisphosphonates are among the most prescribed drugs in medicine, primarily used to prevent fractures in women with osteoporosis. Intriguing observational data have hinted at broader health benefits — reduced cardiovascular mortality, lower cancer rates, and improved survival — but the biological mechanisms behind these extraskeletal effects have remained poorly understood. This landmark multi-omic study provides the most comprehensive mechanistic evidence to date that bisphosphonates act as genuine geroprotective agents.

Researchers applied in vivo spatial transcriptomics to aged mice treated with zoledronate and found striking tissue-level rejuvenation. In the heart, liver, and intestine, cellular composition and gene expression shifted toward patterns characteristic of young animals. Genes governing detoxification, mitochondrial stability, energy metabolism, and antioxidation were all upregulated — a profile that maps directly onto established hallmarks of aging reversal.

In humans, a randomized clinical trial provided plasma samples that underwent a 5,000-plex proteomic panel. Zoledronate treatment significantly altered approximately 400 proteins, with downregulation of markers tied to genomic instability, proteostasis loss, mitochondrial dysfunction, stem cell exhaustion, and senescence-associated secretory phenotype (SASP) components. Fluorescent tracing confirmed that bisphosphonates are taken up by non-skeletal cells, explaining how systemic effects are possible.

Cell culture experiments demonstrated that low, clinically relevant bisphosphonate doses stimulated growth and protected against DNA damage-induced senescence across multiple human cell types, with cardiomyocytes showing the strongest response. Using AlphaFold-powered proteome-wide target deconvolution, the team identified two previously unrecognized bisphosphonate binding partners — PHB2 and ASAH1. Downstream activation of MEF2A was validated as a key mediator of zoledronate's cardioprotective benefits.

These findings reframe bisphosphonates as potential broad-spectrum geroprotectors. Caveats include reliance on the abstract alone, the need for longer human trials with aging endpoints, and the question of whether oral bisphosphonates replicate intravenous zoledronate's effects.